Table 4.
Neurodevelopmental follow-up of 47 survivors having been admitted to ECMO treatment in Graz, Austria, between 1989 and 2016.
| Follow-up data | ECMO survivors n = 28 | Survivors without ECMO, n = 19 |
|---|---|---|
| Lost to follow-up | 2 (7.1) | 10 (53) |
| Follow-up | 26 | 9 |
| Age (months) | 73 (24–276) | 9 (3–72) |
| Normal development | 17 (65) | 7 (78) |
| Cognitive/ motor deficits | 9 (35) | 2 (22) |
| Cognitive deficits | 9 (100) | 2 (100) |
| Developmental delay | 1 (11) | 1 (50) |
| Mental Retardation | 8 (89) | 1 (50) |
| Motor function deficits | 1 (11) | – |
| Athetosis | 1 (100) | – |
| Cerebral palsy | 0 (0) | – |
| Microcephaly | 3 (11.5) | 1 (50) |
| Dystrophy | 1 (3.9) | – |
| Seizures | 1 (3.9) | – |
| Perception disorder | 2 (7.7) | – |
| Attention deficit syndrome | 1 (3.9) | – |
| Learning difficulties | 1 (3.9) | – |
Data are given as n (%) or median (range).